ASCO26: Michael Hassett, MD, MPH, eSyM - Takeaways - MDSpire

ASCO26: Michael Hassett, MD, MPH, eSyM

Dr. Michael Hassett of Dana-Farber Cancer Institute shared new findings showing deployment of eSyM, an ePRO-based, EHR-integrated symptom management program, was associated with statistically significant and potentially meaningful improvements in overall survival. Strategies to improve adoption of ePRO-based symptom management may be warranted.

  • July 1, 2026

Share

  • 1

    Dr. Michael Hassett presented findings on the eSyM program at ASCO26.

  • 2

    eSyM is an ePRO-based, EHR-integrated symptom management program.

  • 3

    The deployment of eSyM was linked to statistically significant improvements in overall survival.

  • 4

    The findings suggest that ePRO-based symptom management could enhance patient outcomes.

  • 5

    Strategies to improve the adoption of ePRO-based symptom management may be necessary.

Original Source(s)

ASCO26: Michael Hassett, MD, MPH, eSyM

  • July 1, 2026

Related Content

ASCO26: Alicia Morgans, MD, MPH, ARACOG

Dr. Alicia Morgans of Dana-Farber Cancer Institute reported at #ASCO26 that ARACOG found darolutamide was associated with less decline in cognitive testing than enzalutamide, which may help guide treatment choice.

  • July 1, 2026

  • 1 min
From voice biomarkers to telemedicine screening: developing and evaluating a voice-based AI model for laryngeal lesion detection using the Bridge2AI-Voice dataset

Case Report: Synchronous minute intramucosal Epstein–Barr virus-associated gastric cancer revealed after short-term Helicobacter pylori eradication